These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16334203)

  • 1. [Any splanchnic vein thrombosis must make look for a forme fruste of myeloproliferative disorder].
    Casadevall N; Valla D
    Rev Prat; 2005 Oct; 55(15):1669-70. PubMed ID: 16334203
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of thrombophilia in splanchnic vein thrombosis.
    Primignani M; Mannucci PM
    Semin Liver Dis; 2008 Aug; 28(3):293-301. PubMed ID: 18814082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
    Brière JB
    Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Portal vein thrombosis as an onset form of silent myeloproliferative chronic syndrome].
    Santaeugenia S; Martí S; Maria Ribera J; Millá F
    Med Clin (Barc); 2006 Oct; 127(15):598-9. PubMed ID: 17145021
    [No Abstract]   [Full Text] [Related]  

  • 5. Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis.
    How J; Trinkaus KM; Oh ST
    Br J Haematol; 2018 Oct; 183(2):310-313. PubMed ID: 29048104
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
    Galtier J; Drevon L; Le Bris Y; Giraudier S; Wemeau M; Legros L; Paz DL; Girodon F; Kiladjian JJ; Mesguich C; Parrens M; Mediavilla C; Roy L; Guy A; Mansier O; Ianotto JC; James C
    Haematologica; 2024 Jun; 109(6):1989-1993. PubMed ID: 38328854
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis.
    Iurlo A; Cattaneo D; Gianelli U; Fermo E; Augello C; Cortelezzi A
    Ann Hematol; 2015 May; 94(5):881-2. PubMed ID: 25377046
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of idiopathic portal vein thrombosis?
    Johnston RD; Chang C; Singh RK; Austin A; El-Omar E
    Gut; 2010 Jan; 59(1):111. PubMed ID: 20007958
    [No Abstract]   [Full Text] [Related]  

  • 9. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.
    Chait Y; Condat B; Cazals-Hatem D; Rufat P; Atmani S; Chaoui D; Guilmin F; Kiladjian JJ; Plessier A; Denninger MH; Casadevall N; Valla D; Brière JB
    Br J Haematol; 2005 May; 129(4):553-60. PubMed ID: 15877740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent venous thrombosis: the sole manifestation of an occult myeloproliferative disease.
    Lang R; Inbal A; Jutrin I; Ravid M
    Isr J Med Sci; 1982 Jun; 18(6):705-7. PubMed ID: 7107208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired and inherited risk factors for splanchnic venous thrombosis.
    De Stefano V; Teofili L; Leone G
    Blood; 2001 May; 97(10):3314-5. PubMed ID: 11368062
    [No Abstract]   [Full Text] [Related]  

  • 12. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity among splanchnic vein thrombosis associated with myeloproliferative neoplasms.
    Cattaneo D; Gianelli U; Bianchi P; Cortelezzi A; Iurlo A
    Eur J Intern Med; 2018 Jun; 52():e25-e26. PubMed ID: 29567096
    [No Abstract]   [Full Text] [Related]  

  • 14. Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis.
    Camerlo S; Ligato J; Rosati G; Carrà G; Russo I; De Gobbi M; Morotti A
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2 46/1 haplotype in splanchnic vein thrombosis.
    Kouroupi E; Kiladjian JJ; Chomienne C; Dosquet C; Bellucci S; Valla D; Cassinat B
    Blood; 2011 May; 117(21):5777-8. PubMed ID: 21617012
    [No Abstract]   [Full Text] [Related]  

  • 16. Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis.
    Kiladjian JJ; Debureaux PE; Plessier A; Soret-Dulphy J; Valla D; Cassinat B; Rautou PE
    J Hepatol; 2021 Jan; 74(1):251-252. PubMed ID: 32988658
    [No Abstract]   [Full Text] [Related]  

  • 17. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
    Rosti V; Bonetti E; Bergamaschi G; Campanelli R; Guglielmelli P; Maestri M; Magrini U; Massa M; Tinelli C; Viarengo G; Villani L; Primignani M; Vannucchi AM; Frassoni F; Barosi G;
    PLoS One; 2010 Dec; 5(12):e15277. PubMed ID: 21151606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience.
    Tremblay D; Vogel AS; Moshier E; Hoffman R; Kremyanskaya M; Zhou S; Schiano T; Mascarenhas J
    Eur J Haematol; 2020 Jan; 104(1):72-73. PubMed ID: 31587352
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatoportal thromboses are no longer idiopathic.
    Blendis L; Wong F
    Gastroenterology; 2000 Sep; 119(3):874-5. PubMed ID: 10982784
    [No Abstract]   [Full Text] [Related]  

  • 20. ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders.
    Moreno MJ; Lozano ML; Ferrer F; Bellosillo B; Besses C; Vicente V; Martínez C
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):390-2. PubMed ID: 19542939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.